There are currently 42 clinical trials in Boynton Beach, Florida looking for participants to engage in research studies. Trials are conducted at various facilities, including Visions Clinical Research, GSK Investigational Site, Florida Eye Microsurgical Institute and Orthopedic Research Institute. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
MRCT Evaluating NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension
NCT04630808
Recruiting
The objective of this clinical study is to evaluate the safety and efficacy of NCX 470 Ophthalmic Solution in lowering intraocular pressure (IOP) in subjecs with ocular hypertension or open-angle glaucoma. Subjects will be randomized in a 1:1 ratio to NCX 470 0.1% or to latanoprost 0.005% to be administered to both eyes once daily in the evening for up to 12 months.
Gender:
All
Ages:
Between 18 years and 84 years
Trial Updated:
02/23/2024
Locations: Nicox Clinical Site, Boynton Beach, Florida
Conditions: Open Angle Glaucoma, Ocular Hypertension
Register for Updates
A Prospective Single-Arm Multicenter StuDy of the BarE TEmporary SPur StEnt System foR the tREatment of Vascular Lesions Located in the infrapoplitEal Arteries beLow the Knee (DEEPER REVEAL)
NCT05358353
Recruiting
This is a prospective, multicenter, single arm study designed to evaluate the safety and efficacy of the Temporary Bare Spur Stent System (Spur Stent System).
Gender:
All
Ages:
18 years and above
Trial Updated:
01/26/2024
Locations: Palm Beach Heart and Vascular, Boynton Beach, Florida
Conditions: Peripheral Arterial Disease, Critical Limb Ischemia
Register for Updates
A Study of Efficacy and Safety of Rosnilimab in Subjects With Moderate to Severe Rheumatoid Arthritis (RENOIR)
NCT06041269
Recruiting
RENOIR Study: This study will evaluate the safety, tolerability, and efficacy of Rosnilimab in subjects with moderate to severe Rheumatoid Arthritis (RA)
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
10/11/2023
Locations: Anaptys Bio Investigative Site 10-118, Boynton Beach, Florida
Conditions: Rheumatoid Arthritis
Register for Updates
Multi-site Study for Evaluation of Clinical Ranges of Whole Blood Clotting Times of Patients on Anticoagulants and Verification of Measurement Precision of Liquid Quality Controls With the Perosphere Technologies' PoC Coagulometer
NCT04868214
Recruiting
The Perosphere Technologies' PoC Coagulometer measures clotting times of fresh whole blood samples. Clotting is initiated by glass surface activation and terminates on optical detection of fibrin assembly, the final step in the coagulation cascade. Since activation occurs at the top of the intrinsic pathway and detection occurs at the bottom of the final common pathway, the Perosphere Technologies' PoC Coagulometer has shown sensitivity to a broad range of drugs and reagents that affect blood cl... Read More
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
09/25/2023
Locations: Perosphere Technologies Inc., Boynton Beach, Florida
Conditions: Coagulation
Register for Updates
KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment
NCT03662126
Recruiting
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with myelofibrosis (MF) who no longer benefit from treatment with a JAK inhibitor. Inhibition of MDM2 is a novel mechanism of action in MF. This study will be conducted in 2 phases. Phase 2 will determine the KRT-232 recommended dose and dosing schedule; Phase 3 will test KRT-232 vs Best Available Therapy (BAT). Patients in the Phase 3 part of the study will be randomized 2:1 to receive ei... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/26/2023
Locations: University Cancer Institute, Boynton Beach, Florida
Conditions: Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Post-Essential Thrombocythemia MF (Post-ET-MF)
Register for Updates
A Study to Monitor Ambulatory Blood Pressure Monitoring in Hypogonadal Men Treated With Nasal Testosterone Gel
NCT04976595
Recruiting
The purpose of this study is to assess the change in 24-hour ambulatory blood pressure monitoring (ABPM) between baseline (Day 0) and Day 120 following 4 months of testosterone therapy with Natesto.
Gender:
Male
Ages:
Between 18 years and 80 years
Trial Updated:
07/04/2022
Locations: Florida Healthcare Associates, Boynton Beach, Florida
Conditions: Hypogonadism
Register for Updates